Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children
- PMID: 15184993
- DOI: 10.1007/s00280-004-0801-6
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children
Abstract
Purpose: To describe mesna excretion in children.
Patients and methods: We studied 14 children (aged 1-18 years) who received 1.8 g/m(2) of ifosfamide per day for 5 days. For uroprotection, the children were given intravenous mesna (equal to 20% of the ifosfamide dose) followed by two oral doses (each equal to 40% of the ifosfamide dose). The concentrations of mesna and the metabolite dimesna were measured in urine samples collected on treatment days 1 and 5.
Results: Of 14 patients enrolled, 11 (aged 4-18 years) were evaluable. The profiles of mesna excretion rates were similar on days 1 and 5. Mesna excretion declined rapidly over 1-2 h after intravenous dosing. Increases in mesna excretion after oral dosing lagged by 2-4 h. About 21% of the mesna administered was excreted unchanged over 24 h on both days 1 and 5. The proportion excreted varied by severalfold between patients, but there was no association with age.
Conclusion: The profile of mesna excretion after intravenous and oral dosing in these children was similar to that in reported studies of ifosfamide-treated adults.
Similar articles
-
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5829-34. Clin Cancer Res. 2003. PMID: 14676103 Clinical Trial.
-
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.Clin Cancer Res. 1997 Sep;3(9):1507-18. Clin Cancer Res. 1997. PMID: 9815837
-
Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.Clin Cancer Res. 1998 Oct;4(10):2313-20. Clin Cancer Res. 1998. PMID: 9796960 Clinical Trial.
-
Oral administration of mesna with ifosfamide.Semin Oncol. 1996 Jun;23(3 Suppl 6):91-6. Semin Oncol. 1996. PMID: 8677457 Review.
-
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.Semin Oncol. 1996 Jun;23(3 Suppl 6):84-90. Semin Oncol. 1996. PMID: 8677456 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources